Finn Myhren

This inventor holds 20 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Aker Biomarine Antarctic as, Norskhydro Asa, Clavis Pharma Asa. Active years: 2000-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Finn Myhren. Retrieved from https://idiyas.com/inventor/finn-myhren

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 8)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 85(Granted Patents)

Location History:

Porsqrunn, NO (2004)
Porsgunn, NO (2013)
Porsgrunn, NO (2000 - 2016)
Oslo, NO (2018 - 2023)
Stamsund, NO (2021 - 2023)

Company Filing History:

8 out of 35

Aker Biomarine Antarctic as

Icahn School of Medicine at Mount Sinai

patents

7. 1 out of 957

The United States Government as Represented by the Department of Veterans Affairs

patents

8. 1 out of 455

University of Alberta

patents

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11819509 - Lipid compositions (2023-11-21),

2. 11744864 - Method of treating eye diseases with krill oil (2023-09-05),

3. 11065267 - Lysophosphatidylcholine compositions (2021-07-20),

4. 11020438 - Phospholipid compositions and their preparation (2021-06-01),

5. 10960016 - Capsules containing high doses of krill phospholipids (2021-03-30),

6. 10864223 - Lipid compositions (2020-12-15),

7. 10806742 - Liquid phospholipid-containing compositions for the preparation of pharmaceuticals (2020-10-20),

8. 10456412 - Lipid extraction processes (2019-10-29),

9. 9867856 - Phospholipid compositions and their preparation (2018-01-16),

10. 9428540 - Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents (2016-08-30),

11. 8912162 - Parenteral formulations of elacytarabine derivatives (2014-12-16),

12. 8722041 - Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof (2014-05-13),

13. 8399420 - Azacytidine analogues and uses thereof (2013-03-19),

14. 8349834 - Dioxolane derivates for the treatment of cancer (2013-01-08),

15. 6762175 - Fatty acid derivatives (2004-07-13),

Title: Inventor Profile: Finn Myhren

Introduction

Finn Myhren is a distinguished inventor based in Porsgrunn, Norway, known for his innovative contributions to pharmaceutical formulations and cancer treatment. With an impressive portfolio of 11 patents, he has made significant strides in the field of medicinal chemistry, particularly through his work on glucocorticoid derivatives.

Latest Patents

Among his latest inventions are two noteworthy patents. The first is titled "Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents." This invention focuses on certain unsaturated fatty acid derivatives of therapeutically active glucocorticoids, offering potential treatment options for inflammatory and cancerous conditions through pharmaceutical formulations. The second patent, "Parenteral formulations of elacytarabine derivatives," pertains to parenteral formulations for long chain saturated and monounsaturated fatty acid derivatives of 1-β-D-arabinofuranosylcytosine (cytarabine). This invention emphasizes the preparation of effective doses for cancer treatment, enhancing patient compliance.

Career Highlights

Finn Myhren has had a notable career, working with reputable companies such as Norsk Hydro ASA and Clavis Pharma ASA. His expertise has been instrumental in advancing the development of innovative therapeutic solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Finn has collaborated with various professionals, including colleagues Are Dalen and Marit Liland Sandvold. These partnerships have fostered a multidisciplinary approach to his research and development efforts, leading to successful innovations.

Conclusion

Finn Myhren stands out as a prolific inventor in the pharmaceutical field, with a focus on innovative solutions for cancer treatment and anti-inflammatory therapies. His patented inventions and collaborative spirit continue to influence the industry, making a lasting impact on healthcare and medicine.

Profile summary based on public USPTO records.